Answers are grounded in this paper and cite their sources.
This paper summarizes data obtained from two separate studies done in our laboratory. Both studies were done to investigate the possibility that drugs commonly applied to the middle ear space could be the cause of sensori‐neural hearing loss. The two drugs that were felt to be the most likely candidates for the studies were neomycin and polymyxin B. In the neomycin study, the various drug concentrations were administered three times a day for four weeks. In the polymyxin B study, the administration was three times a day for two weeks. Cochlear function was evaluated electrophysiologically and by examination of surface preparations of the organ of Corti. The data show that both neomycin and polymyxin B can, in concentrations similar to those found in commercially available otic drops, induce cochlear damage when they are applied to the middle ear space of guinea pigs. The degree of damage produced is dose related. In the case of neomycin, it was shown that the effect worsens as the duration of the dosage administration is extended. This ototoxic effect of the neomycin and polymyxin B solutions on the cochlea are detectable as changes in the ability of the cochlea to generate the AC cochlear potential, as well as by the loss of hair cells as evidenced by surface preparation morphological examination. It is quite apparent that this same degree of cochlear damage is not reported after the clinical use of otic drops containing these drugs either singly or together. We feel that there may be several reasons for this discrepancy: the first, and most obvious, is the anatomical differences between the location of the round window membrane and the middle ear space in man and guinea pig. In the case of the guinea pig, the round window membrane is fully exposed and drugs applied to the middle ear space have ready access to it; however, in the case of the human round window membrane, it is located inside the superior surface of the round window niche. The round window membrane in man is often obstructed by a pseudo‐membrane of epithelium over the opening of the round window niche. In the case of infected ears, a similar type of obstruction could be provided by accumulated pus or cellular debris. It is very conceivable that in many or maybe all patients, entry of drugs into the cochlea through the round window membrane is prevented by these various types of obstruction. A second reason for the discrepancy between the animal studies and absence of ototoxicity reports from patients may be the fact that ototoxicity was not looked for. Two considerations are important here: first it is reported that sensori‐neural hearing loss can be produced by the chronic otitis media for which the drops are being administered. For this reason any sensori‐neural hearing loss observed in patients receiving these drugs might logically be ascribed to the disease and not the treatment. Second, the earliest effects of these drugs appear to be on high‐frequency auditory function. This is best documented in our data by the loss of hair cells in the basal end of the cochlea; furthermore, when drugs such as neomycin are administered parentally it is well documented that the auditory function at high frequencies is the first to be affected. Conventional audiometry measures auditory function only to 8,000 Hz. Bone conduction hearing thresholds are measured to only 4,000 Hz. Despite the limitation of the measurement capabilities of standard audiometers the fact remains that many people can hear frequencies as high as 20,000 Hz. If this auditory function at frequencies above 8,000 Hz is being destroyed by drugs it would not be measured through conventional audiometry. It is our contention that the lack of reported data for ototoxicity resulting from the topical use of otic drop preparations may be due to two circumstances: 1. any detected sensori‐neural hearing loss in patients receiving otic drops for the treatment of chronic otitis media would logically be ascribed to the disease and not the treatment, and 2. the high‐frequency function that these drugs would be most likely to affect first are not measurable by conventional audiometric equipment found in most offices.
No takes yet. Share an insight, caveat, or question.
Brummett et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: